Neos, Teva Reach Settlement on ADHD Drug Patent

Neos and Teva reached a confidential settlement and licensing agreement involving Teva’s ANDA for a generic of Neos’ ADHD drug Cotempla XR-ODT (methylphenidate).

Under the agreement, Teva will have the right to manufacture and market the generic beginning on July 1, 2026 or earlier under certain circumstances. The details of the agreement were otherwise confidential and are subject to approval by the Justice Department and the Federal Trade Commission.

“We are pleased to have reached this settlement and will continue to defend our innovative medicines against any challenge,” said Neos CEO Jerry McLaughlin.